Last updated: February 16, 2026
What is the Drug NDC 58151-0157?
The National Drug Code (NDC) 58151-0157 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy treatment indicated for spinal muscular atrophy (SMA) in pediatric patients under age 2. It is marketed by Novartis Gene Therapies.
Market Overview
Indication and Approval Timeline
Zolgensma was approved by the FDA on May 24, 2019. It is designated as a one-time gene therapy administered intravenously. Approved for patients with SMA type 1, with potential expanded indications based on ongoing clinical studies and regulatory decisions.
Prevalence and Market Size
SMA affects roughly 1 in 10,000 live births globally. In the U.S., estimated at around 8,000 to 10,000 patients eligible for treatment. Advances in diagnostics and newborn screening increase early detection.
Current Market Dynamics
- Pricing: Initial list price set at $2.125 million per treatment in the U.S.
- Reimbursement: Payers negotiate prices, and coverage varies based on formulary management, with many insurers establishing risk-sharing arrangements.
- Market Penetration: Early adoption higher in academic centers, with expanding access via specialty pharmacies.
Competitive Landscape
- Gene Therapies: Limited direct competition — Novartis' Zolgensma currently holds a unique positioning.
- Alternative Treatments: Spinraza (nusinersen) by Biogen, priced at $750,000 first year and $375,000 annually thereafter, remains a standard therapy with different administration routes and dosing regimens.
Price Projections
Short-Term Outlook (Next 12 Months)
- The list price is unlikely to decrease significantly due to the high upfront R&D cost recovery and limited competition.
- Payer coverage will shapes actual transaction prices. Some plans negotiate discounts ranging from 10% to 40%.
- Expected volume growth as awareness increases and neonatal screening expands; however, access barriers may temper rapid adoption.
Medium to Long-Term Outlook (2-5 Years)
- The potential entry of biosimilar gene therapies or competitive products remains unlikely in the near term due to complex manufacturing and regulatory hurdles.
- Price reductions might occur if manufacturing costs decrease or new evidence supports broader or earlier use.
- Price pressure from healthcare policy reforms focusing on cost containment could lead to discounts or outcome-based payment models.
Potential for Pricing Innovation
- Outcomes-based payments and installment-based financing models might influence net prices.
- As evidence accumulates for broader indications or repeat treatments, pricing strategies may adapt accordingly.
Estimation Summary
| Scenario |
Price Range (USD) |
Description |
| Conservative Approach |
$2.125 million |
Maintains current list price, assuming no significant discounts |
| Moderate Discount |
$1.8 - $2.0 million |
10-15% discount negotiated across payers |
| Aggressive Discount |
<$1.8 million |
20-30% discounts with volume incentives or outcome-based agreements |
Cost-Effectiveness Considerations
- Cost per quality-adjusted life year (QALY) saved remains high. Studies suggest the therapy's value depends heavily on long-term health outcomes, which are still under investigation.
- Payers increasingly favor outcome-based models, which could influence final prices.
Regulatory and Policy Impact
- Orphan Drug Designation: Provides market exclusivity until at least 2024 in the U.S., limiting immediate generic or biosimilar competition.
- Price Regulation: Growing momentum towards drug pricing legislation may impact future costs.
Summary
The pricing of NDC 58151-0157 (Zolgensma) is expected to hold near its current level in the near term. Moderate discounts could emerge through negotiated payor agreements. Long-term pricing trajectories are influenced by regulatory, manufacturing, and policy developments, with potential downward pressure from outcome-based payment models and increased market volume.
Key Takeaways
- Zolgensma costs approximately $2.125 million per dose in the U.S.; prices are unlikely to fall sharply soon.
- Market expansion hinges on increased newborn screening and early diagnosis.
- Payer negotiations and outcome-based payment models will influence actual prices.
- Competition remains limited, with Spinraza as the primary alternative.
- Long-term pricing depends on regulatory changes, added indications, and manufacturing costs.
FAQs
1. What factors influence the pricing of gene therapies like Zolgensma?
Manufacturing complexity, R&D costs, regulatory exclusivity, market size, and payer negotiations. Increasing use of outcome-based agreements can also affect net prices.
2. How does Zolgensma compare cost-wise to Spinraza?
Zolgensma is a one-time treatment costing around $2.125 million, while Spinraza incurs ongoing costs of approximately $750,000 initially plus annual maintenance.
3. When might prices for Zolgensma decrease?
If regulatory changes, manufacturing advancements, or increased competition from biosimilars occur; or through negotiated discounts and outcome-based payment models.
4. What is the impact of newborn screening on Zolgensma adoption?
Early detection via newborn screening can increase early treatment eligibility, driving up demand and payers' willingness to reimburse at current prices.
5. Are there any global differences in Zolgensma pricing?
Yes. Price varies across countries due to national reimbursement policies, negotiations, and healthcare system budgets. Countries with centralized healthcare may negotiate lower prices than the U.S.
References
- FDA. Zolgensma (onasemnogene abeparvovec-xioi) approval announcement, 2019.
- Novartis. Zolgensma product information, 2022.
- EvaluatePharma. Gene therapy market data, 2022.
- CDC. Spinal muscular atrophy prevalence and screening, 2022.
- IQVIA. Pharmaceutical pricing and reimbursement reports, 2022.
